Endoscopy-Related Bleeding and Thromboembolic Events in Patients on Direct Oral Anticoagulants or Vitamin K Antagonists

Autor: de Santiago, ER, Aldehuelo, RS, Pons, FR, Escaja, CR, Fernandez-Esparrach, G, Canete-Ruiz, A, Aracil, CF, Perez-Corte, D, Leon, RR, Marcos-Prieto, HM, Delgado-Guillena, PG, Garcia-Rodriguez, A, Guarner-Argente, C, Muriel, A, de la Fuente-Briongos, E, de Paredes, AGG, Parejo-Carbonell, S, Tellez, L, Senosiain-Lalastra, C, Burgos-Santamaria, D, Aicart-Ramos, M, Munoz, BM, Penas-Garcia, B, Pagano, G, Urquiza, GC, Ferreruela, MU, de Jorge-Turrion, MA, Barreiro-Alonso, E, Fraile-Lopez, M, Gomez-Outomuro, A, Altamirano, MI, Esteban, MN, Ruiz-Andreu, M, Arribas-Anta, J, de Frutos, D, Herreros-de-Tejada, A, Arias-Rivera, ML, Roldan-Fernandez, M, Martin, AFM, Zamora, J, Vazquez-Sequeiros, E, Albillos, A
Rok vydání: 2022
Předmět:
Zdroj: Clinical Gastroenterology and Hepatology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 1542-3565
Popis: BACKGROUND & AIMS: Few prospective studies have assessed the safety of direct oral anticoagulants (DOACs) in elective endoscopy. Our primary aim was to compare the risks of endoscopy-related gastrointestinal bleeding and thromboembolic events in patients on DOACs or vitamin K antagonists (VKAs) in this setting. Secondarily, we examined the impact of the timing of anticoagulant resumption on the risk of delayed bleeding in high-risk therapeutic procedures. METHODS: We conducted a multicenter, prospective, observational study from January 2018 to March 2020 of 1602 patients on oral anticoagulants (1004 on VKAs and 598 on DOACs) undergoing 1874 elective endoscopic procedures. Our primary outcomes were 90-day thromboembolic events and 30-day endoscopy-related gastrointestinal bleeding. The inverse probability of treatment weighting propensity score method was used for baseline covariate adjustment. RESULTS: The 2 groups had similar risks of endoscopy-related gastrointestinal bleeding (VKAs vs DOACs, 6.2% vs 6.7%; adjusted odds ratio [OR], 1.05; 95% CI, 0.67-1.65) and thromboembolic events (VKAs vs DOACs, 1.3% vs 1.5%; adjusted OR, 0.90; 95% CI, 0.34-2.38). In high bleeding risk procedures (n = 747), delayed anticoagulant resumption (> 48 hours or 24-48 hours vs < 24 hours) did not reduce the risk of postprocedural bleeding (10.3%, 9%, and 5.8%, respectively; adjusted P = .43). Hot and cold snare polypectomy were the most frequent high-risk interventions (41.8% and 39.8%, respectively). CONCLUSION: In a prospective study of patients on DOACs or VKAs undergoing elective endoscopy, endoscopyrelated bleeding and thromboembolic events showed similar risk. Our study suggests that early anticoagulant resumption is safe in most patients, but more data are needed for advanced high-risk therapeutic procedures.
Databáze: OpenAIRE
Externí odkaz: